---
title: "Ernexa Therapeutics Inc. (ERNA.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ERNA.US.md"
symbol: "ERNA.US"
name: "Ernexa Therapeutics Inc."
industry: "生物技術"
---

# Ernexa Therapeutics Inc. (ERNA.US)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 美股市場 |
| Website | [www.ernexatx.com](https://www.ernexatx.com) |

## Company Profile

Ernexa Therapeutics Inc.是一家處于臨床前階段的公司，開發用于治療實體腫瘤和自身免疫疾病的誘導來源間充質幹細胞（iMSC）療法。該公司的主要產品是 ERNA-101，一種分泌促炎細胞因子（IL-7/IL-15）的同種異體 iMSC，用于治療卵巢癌；以及 ERNA-102，一種分泌抗炎細胞因子（IL-10）的 iMSC，用于治療類風濕關節炎。公司與 Factor Bioscience Limited 簽訂了許可協議。該公司之前被稱為 Eterna Therapeutics Inc

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-18T04:30:14.000Z

**Overall: D (0.66)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 316 / 402 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -99.83% |  |
| Net Profit YoY | 59.16% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 2.51 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8.94M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 1000.00 |  |


**Multi Score**: D

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 87.78% | A |
| Profit Margin | -1834100.00% | E |
| Gross Margin | 0.00% | E |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -99.83% | E |
| Net Profit YoY | 59.16% | B |
| Total Assets YoY | -20.03% | E |
| Net Assets YoY | 107.86% | A |

#### Cash Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -0.01% | D |
| OCF YoY | -99.83% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 42.16% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Ernexa Therapeutics Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "87.78%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-1834100.00%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-99.83%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "59.16%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-20.03%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "107.86%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "E",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-0.01%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-99.83%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "42.16%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制藥 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | OpGen (US.OPGN) | B | A | A | A | B | A |
| 05 | 艾伯維 (US.ABBV) | A | C | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.53 | 142/603 | - | - | - |
| PB | 2.71 | 212/603 | 5.56 | 2.73 | 2.23 |
| PS (TTM) | 9669.39 | 318/603 | 9418.67 | 25.32 | 19.49 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2022-10-12T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 0 | 0% |
| Hold | 1 | 100% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.36 |

## References

- [Company Overview](https://longbridge.com/en/quote/ERNA.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ERNA.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ERNA.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.